speb/financial-data huggingface dataset:
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 9546951893.14
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 13086100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 86045100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 1541400000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 20812900000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 13385200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 34812100000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 4647300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -653300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -209248106.86
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 4287200000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.32
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 72959000000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -653300000.00
AUROPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -653300000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 148187700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 40000600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 333847400000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 87515000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 55672700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 55672700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 70943700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 70943700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 7449400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 7449400000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 580870113.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 15.86
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 55637900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -31046700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 3966400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 3966400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 580800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 71914000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 71914000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 107184800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 107184800000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -2324000000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -14997600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -2646800000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 16178900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 12815700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -11707300000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 1639300000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 7986100000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 580800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 580800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 378909700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 378909700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: 0.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 30088300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 30088300000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 134883600000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 34290700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 327087500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 327087500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 1037000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 1037000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 68734500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 68734500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 69771500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 69771500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 180390100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 180390100000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 3530400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 3530400000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 17781900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 17781900000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 17781900000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 4785700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 17781900000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 4785700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 580870113.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 15.86
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 35047500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 9212600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 22700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 54958200000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 13888200000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 72740100000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 18673900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 8288200000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 71914000000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -12691500000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 24217000000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -36900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 243000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill: 8001500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 8001500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 52813800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 52813800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 173387600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 173387600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Gross Profit: 198963800000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 53224300000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense: 3839700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 982100000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 3839700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 982100000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -3440900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 3285600000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Inventory: 120529400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 120529400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 455671700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 455671700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -34586100000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 7449400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 7449400000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 3606800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 2929400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 2929400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 8027500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 8027500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 10956900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 10956900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 3606800000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -13039800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 1088400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 1088400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 4004100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 4004100000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Minority Interest: -81600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: -81600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Minority Interests: 17800000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 4200000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -31700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Debt: 4848000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 4848000000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 2209800000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income: 35047500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income: 9212600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 35047500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 9212600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 35029700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 9208400000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 35047500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 9212600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 35047500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 9212600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 51118500000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 35029700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 9208400000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: -4189000000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Interest Income: -3839700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -982100000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -10818900000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -5841200000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -9433000000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -3839700000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -982100000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 3540400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 173387600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 173387600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -26395200000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 3591800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 326095900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 326095900000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 14835900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 14835900000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3060000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3060000000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 73393400000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 18673900000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Normalized Income: 35495183382.92
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 9212600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 55263700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Operating Income: 50776100000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 13223700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 333847400000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 87515000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 580801623.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 580801623.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: 1800000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 28034100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 28034100000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 6263000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 6263000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 378328900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 378328900000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 44812300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 44812300000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 193400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 3758900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 3758900000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 5363600000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 5363600000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 4920900000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 1170400000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 81187500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 22493500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 143299300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 143299300000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 178700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 178700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 35270800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 35270800000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Other Special Charges: 653300000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Payables: 57778700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 57778700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Pretax Income: 51118500000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 12906100000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 132600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -31700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -4189000000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -10877600000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -26857700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 134883600000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 34290700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 17781900000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 4785700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -13039800000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Repurchase Of Capital Stock: 0.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 58700000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 462500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 580801623.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 580801623.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Special Income Charges: -653300000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 378909700000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 378909700000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 326095900000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 326095900000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -205616617.08
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Tax Provision: 16088800000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 3697700000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.31
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.29
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 216800000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 216800000.00
AUROPHARMA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -18320300000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 585021500000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 585021500000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 386937200000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 386937200000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 80728400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 80728400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 378828100000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 378828100000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Total Expenses: 283071300000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 74291300000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 206193400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 206193400000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 257934000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 257934000000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 25803300000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 25803300000.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 2106000000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 2106000000.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -653300000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
AUROPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -653300000.00
AUROPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AUROPHARMA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 146697400000.00
AUROPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 146697400000.00
AURR.L income_statement (annual, 2021-12-31) — +Operating Expense: 1621000.00
AURR.L income_statement (annual, 2021-12-31) — +Total Revenue: 5268000.00
AURR.L balance_sheet (annual, 2021-12-31) — Accounts Payable: 772000.00
AURR.L balance_sheet (annual, 2021-12-31) — Accounts Receivable: 807000.00
AURR.L balance_sheet (annual, 2021-12-31) — Accumulated Depreciation: -1082000.00
AURR.L balance_sheet (annual, 2021-12-31) — Additional Paid In Capital: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Allowance For Doubtful Accounts Receivable: 0.00
AURR.L income_statement (annual, 2021-12-31) — Amortization: 3523.00
AURR.L cash_flow (annual, 2021-12-31) — Amortization Cash Flow: 4000.00
AURR.L income_statement (annual, 2021-12-31) — Basic Average Shares: 41666667.00
AURR.L income_statement (annual, 2021-12-31) — Basic EPS: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Beginning Cash Position: 1603000.00
AURR.L cash_flow (annual, 2021-12-31) — Capital Expenditure: -1221000.00
AURR.L cash_flow (annual, 2021-12-31) — Capital Expenditure Reported: -1174000.00
AURR.L balance_sheet (annual, 2021-12-31) — Capital Lease Obligations: 181000.00
AURR.L balance_sheet (annual, 2021-12-31) — Capital Stock: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Cash And Cash Equivalents: 1290000.00
AURR.L balance_sheet (annual, 2021-12-31) — Cash Cash Equivalents And Short Term Investments: 1290000.00
AURR.L cash_flow (annual, 2021-12-31) — Cash Dividends Paid: -100000.00
AURR.L cash_flow (annual, 2021-12-31) — Change In Inventory: -156000.00
AURR.L cash_flow (annual, 2021-12-31) — Change In Payable: 273000.00
AURR.L cash_flow (annual, 2021-12-31) — Change In Receivables: -172000.00
AURR.L cash_flow (annual, 2021-12-31) — Change In Working Capital: -55000.00
AURR.L cash_flow (annual, 2021-12-31) — Changes In Cash: -313000.00
AURR.L balance_sheet (annual, 2021-12-31) — Common Stock: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Common Stock Dividend Paid: -100000.00
AURR.L balance_sheet (annual, 2021-12-31) — Common Stock Equity: 3524000.00
AURR.L cash_flow (annual, 2021-12-31) — Common Stock Issuance: 0.00
AURR.L income_statement (annual, 2021-12-31) — Cost Of Revenue: 3446000.00
AURR.L balance_sheet (annual, 2021-12-31) — Current Assets: 3560000.00
AURR.L balance_sheet (annual, 2021-12-31) — Current Capital Lease Obligation: 155000.00
AURR.L balance_sheet (annual, 2021-12-31) — Current Debt: 30000.00
AURR.L balance_sheet (annual, 2021-12-31) — Current Debt And Capital Lease Obligation: 185000.00
AURR.L balance_sheet (annual, 2021-12-31) — Current Liabilities: 1264000.00
AURR.L cash_flow (annual, 2021-12-31) — Deferred Tax: 106000.00
AURR.L cash_flow (annual, 2021-12-31) — Depreciation: 184000.00
AURR.L cash_flow (annual, 2021-12-31) — Depreciation And Amortization: 188000.00
AURR.L income_statement (annual, 2021-12-31) — Depreciation And Amortization In Income Statement: 188329.00
AURR.L income_statement (annual, 2021-12-31) — Depreciation Income Statement: 184806.00
AURR.L income_statement (annual, 2021-12-31) — Diluted Average Shares: 41666667.00
AURR.L income_statement (annual, 2021-12-31) — Diluted EPS: 0.00
AURR.L income_statement (annual, 2021-12-31) — Diluted NI Availto Com Stockholders: 72000.00
AURR.L income_statement (annual, 2021-12-31) — EBIT: 201000.00
AURR.L income_statement (annual, 2021-12-31) — EBITDA: 389000.00
AURR.L cash_flow (annual, 2021-12-31) — Effect Of Exchange Rate Changes: 0.00
AURR.L cash_flow (annual, 2021-12-31) — End Cash Position: 1290000.00
AURR.L cash_flow (annual, 2021-12-31) — Financing Cash Flow: -303000.00
AURR.L balance_sheet (annual, 2021-12-31) — Finished Goods: 420000.00
AURR.L cash_flow (annual, 2021-12-31) — Free Cash Flow: -893000.00
AURR.L cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: 1000.00
AURR.L cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 59.00
AURR.L income_statement (annual, 2021-12-31) — General And Administrative Expense: 1789000.00
AURR.L balance_sheet (annual, 2021-12-31) — Goodwill And Other Intangible Assets: 4394000.00
AURR.L balance_sheet (annual, 2021-12-31) — Gross Accounts Receivable: 807000.00
AURR.L balance_sheet (annual, 2021-12-31) — Gross PPE: 1319000.00
AURR.L income_statement (annual, 2021-12-31) — Gross Profit: 1822000.00
AURR.L income_statement (annual, 2021-12-31) — Interest Expense: 23000.00
AURR.L income_statement (annual, 2021-12-31) — Interest Expense Non Operating: 23000.00
AURR.L income_statement (annual, 2021-12-31) — Interest Income: 0.00
AURR.L income_statement (annual, 2021-12-31) — Interest Income Non Operating: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Interest Paid Cff: -23000.00
AURR.L cash_flow (annual, 2021-12-31) — Interest Paid Cfo: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Interest Received Cfi: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Inventory: 778000.00
AURR.L balance_sheet (annual, 2021-12-31) — Invested Capital: 3639000.00
AURR.L cash_flow (annual, 2021-12-31) — Investing Cash Flow: -338000.00
AURR.L cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Long Term Capital Lease Obligation: 26000.00
AURR.L balance_sheet (annual, 2021-12-31) — Long Term Debt: 85000.00
AURR.L balance_sheet (annual, 2021-12-31) — Long Term Debt And Capital Lease Obligation: 111000.00
AURR.L cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
AURR.L cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -17000.00
AURR.L balance_sheet (annual, 2021-12-31) — Machinery Furniture Equipment: 490000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 0.00
AURR.L income_statement (annual, 2021-12-31) — Net Income: 72000.00
AURR.L income_statement (annual, 2021-12-31) — Net Income Common Stockholders: 72000.00
AURR.L income_statement (annual, 2021-12-31) — Net Income Continuous Operations: 72000.00
AURR.L income_statement (annual, 2021-12-31) — Net Income From Continuing And Discontinued Operation: 72000.00
AURR.L income_statement (annual, 2021-12-31) — Net Income From Continuing Operation Net Minority Interest: 72000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Income From Continuing Operations: 72000.00
AURR.L income_statement (annual, 2021-12-31) — Net Income Including Noncontrolling Interests: 72000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Intangibles Purchase And Sale: -31000.00
AURR.L income_statement (annual, 2021-12-31) — Net Interest Income: -23000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: -17000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: -17000.00
AURR.L income_statement (annual, 2021-12-31) — Net Non Operating Interest Income Expense: -23000.00
AURR.L cash_flow (annual, 2021-12-31) — Net Other Investing Changes: 847000.00
AURR.L balance_sheet (annual, 2021-12-31) — Net PPE: 237000.00
AURR.L cash_flow (annual, 2021-12-31) — Net PPE Purchase And Sale: -16000.00
AURR.L balance_sheet (annual, 2021-12-31) — Net Tangible Assets: -870000.00
AURR.L balance_sheet (annual, 2021-12-31) — Non Current Deferred Revenue: 2944000.00
AURR.L balance_sheet (annual, 2021-12-31) — Non Current Deferred Taxes Assets: 3000.00
AURR.L balance_sheet (annual, 2021-12-31) — Non Current Deferred Taxes Liabilities: 351000.00
AURR.L income_statement (annual, 2021-12-31) — Normalized EBITDA: 389000.00
AURR.L income_statement (annual, 2021-12-31) — Normalized Income: 72000.00
AURR.L cash_flow (annual, 2021-12-31) — Operating Cash Flow: 328000.00
AURR.L income_statement (annual, 2021-12-31) — Operating Income: 201000.00
AURR.L income_statement (annual, 2021-12-31) — Operating Revenue: 5268000.00
AURR.L balance_sheet (annual, 2021-12-31) — Ordinary Shares Number: 41666667.00
AURR.L balance_sheet (annual, 2021-12-31) — Other Intangible Assets: 4394000.00
AURR.L cash_flow (annual, 2021-12-31) — Other Non Cash Items: -26000.00
AURR.L income_statement (annual, 2021-12-31) — Other Operating Expenses: 1636461.00
AURR.L balance_sheet (annual, 2021-12-31) — Other Payable: 22000.00
AURR.L balance_sheet (annual, 2021-12-31) — Other Properties: 145000.00
AURR.L balance_sheet (annual, 2021-12-31) — Other Receivables: 347000.00
AURR.L income_statement (annual, 2021-12-31) — Other Special Charges: -23000.00
AURR.L income_statement (annual, 2021-12-31) — Otherunder Preferred Stock Dividend: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Payables: 969000.00
AURR.L balance_sheet (annual, 2021-12-31) — Prepaid Assets: 14000.00
AURR.L income_statement (annual, 2021-12-31) — Pretax Income: 178000.00
AURR.L balance_sheet (annual, 2021-12-31) — Properties: 684000.00
AURR.L cash_flow (annual, 2021-12-31) — Purchase Of Intangibles: -31000.00
AURR.L cash_flow (annual, 2021-12-31) — Purchase Of PPE: -16000.00
AURR.L balance_sheet (annual, 2021-12-31) — Raw Materials: 350000.00
AURR.L income_statement (annual, 2021-12-31) — Reconciled Cost Of Revenue: 3446000.00
AURR.L income_statement (annual, 2021-12-31) — Reconciled Depreciation: 188000.00
AURR.L cash_flow (annual, 2021-12-31) — Repayment Of Debt: -17000.00
AURR.L balance_sheet (annual, 2021-12-31) — Retained Earnings: 3524000.00
AURR.L income_statement (annual, 2021-12-31) — Selling General And Administration: 1789000.00
AURR.L balance_sheet (annual, 2021-12-31) — Share Issued: 41666667.00
AURR.L income_statement (annual, 2021-12-31) — Special Income Charges: 36000.00
AURR.L cash_flow (annual, 2021-12-31) — Stock Based Compensation: 0.00
AURR.L balance_sheet (annual, 2021-12-31) — Stockholders Equity: 3524000.00
AURR.L balance_sheet (annual, 2021-12-31) — Tangible Book Value: -870000.00
AURR.L income_statement (annual, 2021-12-31) — Tax Effect Of Unusual Items: 0.00
AURR.L income_statement (annual, 2021-12-31) — Tax Provision: 106000.00
AURR.L income_statement (annual, 2021-12-31) — Tax Rate For Calcs: 0.19
AURR.L balance_sheet (annual, 2021-12-31) — Taxes Receivable: 324000.00
AURR.L cash_flow (annual, 2021-12-31) — Taxes Refund Paid: 42000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Assets: 8194000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Capitalization: 3609000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Debt: 296000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Equity Gross Minority Interest: 3524000.00
AURR.L income_statement (annual, 2021-12-31) — Total Expenses: 5067000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Liabilities Net Minority Interest: 4670000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Non Current Assets: 4634000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Non Current Liabilities Net Minority Interest: 3406000.00
AURR.L income_statement (annual, 2021-12-31) — Total Operating Income As Reported: 201000.00
AURR.L balance_sheet (annual, 2021-12-31) — Total Tax Payable: 175000.00
AURR.L income_statement (annual, 2021-12-31) — Total Unusual Items: 36000.00
AURR.L income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: 36000.00
AURR.L balance_sheet (annual, 2021-12-31) — Work In Process: 8000.00
AURR.L balance_sheet (annual, 2021-12-31) — Working Capital: 2296000.00
AURR.L income_statement (annual, 2021-12-31) — Write Off: -36000.00
AURR.L income_statement (annual, 2022-12-31) — +Operating Expense: 4291000.00
AURR.L income_statement (annual, 2022-12-31) — +Total Revenue: 5302000.00
AURR.L balance_sheet (annual, 2022-12-31) — Accounts Payable: 716000.00
AURR.L balance_sheet (annual, 2022-12-31) — Accounts Receivable: 1193000.00
AURR.L balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -1280000.00
AURR.L balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 7103000.00
AURR.L balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -12000.00
AURR.L cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 172000.00
AURR.L income_statement (annual, 2022-12-31) — Basic Average Shares: 18721737.00
AURR.L income_statement (annual, 2022-12-31) — Basic EPS: -0.12
AURR.L cash_flow (annual, 2022-12-31) — Beginning Cash Position: 1290000.00
AURR.L cash_flow (annual, 2022-12-31) — Capital Expenditure: -1241000.00
AURR.L cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -1155000.00
AURR.L balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 211000.00
AURR.L balance_sheet (annual, 2022-12-31) — Capital Stock: 83000.00
AURR.L balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 5386000.00
AURR.L balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 5386000.00
AURR.L cash_flow (annual, 2022-12-31) — Change In Inventory: -153000.00
AURR.L cash_flow (annual, 2022-12-31) — Change In Payable: 58000.00
AURR.L cash_flow (annual, 2022-12-31) — Change In Receivables: -367000.00
AURR.L cash_flow (annual, 2022-12-31) — Change In Working Capital: -462000.00
AURR.L cash_flow (annual, 2022-12-31) — Changes In Cash: 4097000.00
AURR.L balance_sheet (annual, 2022-12-31) — Common Stock: 83000.00
AURR.L cash_flow (annual, 2022-12-31) — Common Stock Dividend Paid: 0.00
AURR.L balance_sheet (annual, 2022-12-31) — Common Stock Equity: 8634000.00
AURR.L cash_flow (annual, 2022-12-31) — Common Stock Issuance: 7136000.00
AURR.L income_statement (annual, 2022-12-31) — Cost Of Revenue: 3483000.00
AURR.L balance_sheet (annual, 2022-12-31) — Current Assets: 8023000.00
AURR.L balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 79000.00
AURR.L balance_sheet (annual, 2022-12-31) — Current Debt: 30000.00
AURR.L balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 109000.00
AURR.L balance_sheet (annual, 2022-12-31) — Current Liabilities: 1469000.00
AURR.L cash_flow (annual, 2022-12-31) — Deferred Tax: -301000.00
AURR.L cash_flow (annual, 2022-12-31) — Depreciation: 208000.00
AURR.L cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 380000.00
AURR.L income_statement (annual, 2022-12-31) — Diluted Average Shares: 18721737.00
AURR.L income_statement (annual, 2022-12-31) — Diluted EPS: -0.12
AURR.L income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — EBIT: -2470000.00
AURR.L income_statement (annual, 2022-12-31) — EBITDA: -2090000.00
AURR.L cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -1000.00
AURR.L cash_flow (annual, 2022-12-31) — End Cash Position: 5386000.00
AURR.L cash_flow (annual, 2022-12-31) — Financing Cash Flow: 6903000.00
AURR.L balance_sheet (annual, 2022-12-31) — Finished Goods: 311000.00
AURR.L cash_flow (annual, 2022-12-31) — Free Cash Flow: -3523000.00
AURR.L income_statement (annual, 2022-12-31) — General And Administrative Expense: 4569000.00
AURR.L balance_sheet (annual, 2022-12-31) — Goodwill: 0.00
AURR.L balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 5403000.00
AURR.L balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 1205000.00
AURR.L balance_sheet (annual, 2022-12-31) — Gross PPE: 1586000.00
AURR.L income_statement (annual, 2022-12-31) — Gross Profit: 1819000.00
AURR.L income_statement (annual, 2022-12-31) — Interest Expense: 26000.00
AURR.L income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 26000.00
AURR.L income_statement (annual, 2022-12-31) — Interest Income: 2000.00
AURR.L income_statement (annual, 2022-12-31) — Interest Income Non Operating: 2000.00
AURR.L cash_flow (annual, 2022-12-31) — Interest Paid Cff: -21000.00
AURR.L cash_flow (annual, 2022-12-31) — Interest Paid Cfo: -2000.00
AURR.L cash_flow (annual, 2022-12-31) — Interest Received Cfi: 2000.00
AURR.L balance_sheet (annual, 2022-12-31) — Inventory: 931000.00
AURR.L balance_sheet (annual, 2022-12-31) — Invested Capital: 8719000.00
AURR.L cash_flow (annual, 2022-12-31) — Investing Cash Flow: -524000.00
AURR.L cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 7136000.00
AURR.L balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 132000.00
AURR.L balance_sheet (annual, 2022-12-31) — Long Term Debt: 55000.00
AURR.L balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 187000.00
AURR.L cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -30000.00
AURR.L balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 557000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
AURR.L cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 7136000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -2195000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -2195000.00
AURR.L income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -2195000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -24000.00
AURR.L income_statement (annual, 2022-12-31) — Net Interest Income: -24000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -30000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -30000.00
AURR.L income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -24000.00
AURR.L cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 715000.00
AURR.L balance_sheet (annual, 2022-12-31) — Net PPE: 306000.00
AURR.L cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -62000.00
AURR.L balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 3231000.00
AURR.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 3442000.00
AURR.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 0.00
AURR.L balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 0.00
AURR.L income_statement (annual, 2022-12-31) — Normalized EBITDA: -2090000.00
AURR.L income_statement (annual, 2022-12-31) — Normalized Income: -2195000.00
AURR.L cash_flow (annual, 2022-12-31) — Operating Cash Flow: -2282000.00
AURR.L income_statement (annual, 2022-12-31) — Operating Income: -2472000.00
AURR.L income_statement (annual, 2022-12-31) — Operating Revenue: 5302000.00
AURR.L balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 41666667.00
AURR.L balance_sheet (annual, 2022-12-31) — Other Equity Interest: 143000.00
AURR.L balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 5403000.00
AURR.L cash_flow (annual, 2022-12-31) — Other Non Cash Items: -83000.00
AURR.L balance_sheet (annual, 2022-12-31) — Other Properties: 145000.00
AURR.L balance_sheet (annual, 2022-12-31) — Other Receivables: 89000.00
AURR.L income_statement (annual, 2022-12-31) — Other Special Charges: -171000.00
AURR.L income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
AURR.L balance_sheet (annual, 2022-12-31) — Payables: 889000.00
AURR.L balance_sheet (annual, 2022-12-31) — Prepaid Assets: 187000.00
AURR.L income_statement (annual, 2022-12-31) — Pretax Income: -2496000.00
AURR.L balance_sheet (annual, 2022-12-31) — Properties: 884000.00
AURR.L cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
AURR.L cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -24000.00
AURR.L cash_flow (annual, 2022-12-31) — Purchase Of PPE: -62000.00
AURR.L balance_sheet (annual, 2022-12-31) — Raw Materials: 599000.00
AURR.L income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 3483000.00
AURR.L income_statement (annual, 2022-12-31) — Reconciled Depreciation: 380000.00
AURR.L cash_flow (annual, 2022-12-31) — Repayment Of Debt: -30000.00
AURR.L balance_sheet (annual, 2022-12-31) — Retained Earnings: 1307000.00
AURR.L income_statement (annual, 2022-12-31) — Selling General And Administration: 4569000.00
AURR.L balance_sheet (annual, 2022-12-31) — Share Issued: 41666667.00
AURR.L income_statement (annual, 2022-12-31) — Special Income Charges: 171000.00
AURR.L cash_flow (annual, 2022-12-31) — Stock Based Compensation: 143000.00
AURR.L balance_sheet (annual, 2022-12-31) — Stockholders Equity: 8634000.00
AURR.L balance_sheet (annual, 2022-12-31) — Tangible Book Value: 3231000.00
AURR.L income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
AURR.L income_statement (annual, 2022-12-31) — Tax Provision: -301000.00
AURR.L income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.12
AURR.L balance_sheet (annual, 2022-12-31) — Taxes Receivable: 237000.00
AURR.L cash_flow (annual, 2022-12-31) — Taxes Refund Paid: 238000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Assets: 13732000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Capitalization: 8689000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Debt: 296000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 8634000.00
AURR.L income_statement (annual, 2022-12-31) — Total Expenses: 7774000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 5098000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 5709000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 3629000.00
AURR.L income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -2472000.00
AURR.L balance_sheet (annual, 2022-12-31) — Total Tax Payable: 173000.00
AURR.L income_statement (annual, 2022-12-31) — Total Unusual Items: 171000.00
AURR.L income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 171000.00
AURR.L balance_sheet (annual, 2022-12-31) — Work In Process: 21000.00
AURR.L balance_sheet (annual, 2022-12-31) — Working Capital: 6554000.00
AURR.L income_statement (annual, 2023-12-31) — +Operating Expense: 5513000.00
AURR.L income_statement (annual, 2023-12-31) — +Total Revenue: 6628000.00
AURR.L balance_sheet (annual, 2023-12-31) — Accounts Payable: 1022000.00
AURR.L balance_sheet (annual, 2023-12-31) — Accounts Receivable: 1820000.00
AURR.L balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -870000.00
AURR.L balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 10927000.00
AURR.L balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -37000.00
AURR.L cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 294000.00
AURR.L income_statement (annual, 2023-12-31) — Basic Average Shares: 42177356.00
AURR.L income_statement (annual, 2023-12-31) — Basic EPS: -0.09
AURR.L cash_flow (annual, 2023-12-31) — Beginning Cash Position: 5386000.00
AURR.L cash_flow (annual, 2023-12-31) — Capital Expenditure: -1088000.00
AURR.L cash_flow (annual, 2023-12-31) — Capital Expenditure Reported: -813000.00
AURR.L balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 500000.00
AURR.L balance_sheet (annual, 2023-12-31) — Capital Stock: 91000.00
AURR.L balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 3462000.00
AURR.L balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 3462000.00
AURR.L cash_flow (annual, 2023-12-31) — Change In Inventory: -767000.00
AURR.L cash_flow (annual, 2023-12-31) — Change In Payable: 523000.00
AURR.L cash_flow (annual, 2023-12-31) — Change In Receivables: -619000.00
AURR.L cash_flow (annual, 2023-12-31) — Change In Working Capital: -863000.00
AURR.L cash_flow (annual, 2023-12-31) — Changes In Cash: -1926000.00
AURR.L balance_sheet (annual, 2023-12-31) — Common Stock: 91000.00
AURR.L balance_sheet (annual, 2023-12-31) — Common Stock Equity: 8864000.00
AURR.L cash_flow (annual, 2023-12-31) — Common Stock Issuance: 3832000.00
AURR.L income_statement (annual, 2023-12-31) — Cost Of Revenue: 5152000.00
AURR.L balance_sheet (annual, 2023-12-31) — Current Assets: 7807000.00
AURR.L balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 216000.00
AURR.L balance_sheet (annual, 2023-12-31) — Current Debt: 30000.00
AURR.L balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 246000.00
AURR.L balance_sheet (annual, 2023-12-31) — Current Liabilities: 2281000.00
AURR.L cash_flow (annual, 2023-12-31) — Deferred Tax: -90000.00
AURR.L cash_flow (annual, 2023-12-31) — Depreciation: 274000.00
AURR.L cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 568000.00
AURR.L income_statement (annual, 2023-12-31) — Diluted Average Shares: 42177356.00
AURR.L income_statement (annual, 2023-12-31) — Diluted EPS: -0.09
AURR.L income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -3917000.00
AURR.L income_statement (annual, 2023-12-31) — EBIT: -3961000.00
AURR.L income_statement (annual, 2023-12-31) — EBITDA: -3393000.00
AURR.L cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 2000.00
AURR.L cash_flow (annual, 2023-12-31) — End Cash Position: 3462000.00
AURR.L cash_flow (annual, 2023-12-31) — Financing Cash Flow: 3558000.00